Abstract
The safety of tenovir disoproxil fumarate (TDF) was assessed in two double-blind, placebo-controlled studies. Furthermore, we retrospectively collected 19 cases of TDF-associated tubular dysfunction. The incidence of renal events was similar among the active TDF groups and the placebo group in the two double-blind, placebo-controlled studies. Proximal tubulopathy was diagnosed 6.89 +/- 5.51 months after TDF therapy started. All abnormalities normalized within 4.7 +/- 2.94 weeks after drug discontinuation.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Adenine / adverse effects*
-
Adenine / analogs & derivatives*
-
Adenine / therapeutic use
-
Adult
-
Anti-HIV Agents / adverse effects*
-
Anti-HIV Agents / therapeutic use
-
Double-Blind Method
-
Female
-
HIV Infections / drug therapy
-
Humans
-
Kidney Diseases / chemically induced*
-
Male
-
Middle Aged
-
Organophosphonates*
-
Organophosphorus Compounds / adverse effects*
-
Organophosphorus Compounds / therapeutic use
-
Reverse Transcriptase Inhibitors / adverse effects*
-
Reverse Transcriptase Inhibitors / therapeutic use
-
Tenofovir
Substances
-
Anti-HIV Agents
-
Organophosphonates
-
Organophosphorus Compounds
-
Reverse Transcriptase Inhibitors
-
Tenofovir
-
Adenine